In conclusion, our findings suggest that atezolizumab is unlikely to be a cost-effective option as first-line treatment for Chinese patients with metastatic NSCLC regardless of PD-L1 expression status. The gene discussed is CD274; the disease is non-small cell lung carcinoma.